---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331138"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2026-08-04T01:00:20+00:00"
generated_at: "2026-08-04T10:05:51.870269+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lantheus to be acquired by Curium for $102.50/share plus up to $12.00 in CVRs

## Summary
- Total consideration up to $114.50/share: $102.50 cash plus CVRs tied to commercial milestones for prostate cancer, neurology, and DEFINITY franchises.
- CVR milestones: Global Prostate Cancer Diagnostics sales >$950M triggers $1/share, up to $2/share for >$1.75B.
- Transaction expected to close by May 2, 2027, subject to stockholder and regulatory approvals; no financing condition.
- Termination fees: Parent pays $385M (or $100M regulatory) to Lantheus; Lantheus pays $228M to Parent.
- Board approved $6M transaction bonus pool; $4M to CEO Mary Anne Heino and $500K to CFO Daniel Niedzwiecki, payable at closing.

## SEC filing metadata
- accession: 0001193125-26-331138
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2026-08-04T01:00:20+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/0001193125-26-331138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/d167446d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331138
- JSON: https://secwatch.observer/filing/0001193125-26-331138.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.